Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
7m ago CONCORDIA MARITIME : signs time-charter contract for two P-MAX tankers and launches a pool with four vessels
7m agoDJEUROPE MARKETS : European Oil Stocks Hit After OPEC Keeps Production Target
7m ago RESEARCH AND MARKETS : Biostimulants Market Opportunities and Forecasts Report 2019 - Active Ingredient, Application Type, Crop Type & Region Analysis of the $2.5 Billion Industry
8m ago MONGOLIA GROWTH : October 2014 CEO Communiqué to Shareholders
9m ago E ON SE : Enbridge buys 80 per cent stake in U.S. wind power farms from E.ON
9m ago INGRAM MICRO : Looks to Strengthen Position as a Leading Global Provider of Device Lifecycle Services; Makes Binding Offer for the Acquisition of ANOVO
9m ago DIAGEO : Total Voting Rights
12m ago BMW not interested in buying stake in Tesla - Wirtschaftswoche
12m agoDJWal-Mart, Target Report Strong Thanksgiving Day Traffic--3rd Update
12m ago RESEARCH AND MARKETS : Vertical & Horizontal Worlds of Mobile 2014-2017
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : Currys PC World stands poised for one order every second on Black Friday
AUGEAN : Chairman Buys 55,000 Shares (DIRECTOR DEALINGS)
MJ GLEESON : Expects Results To Beat Expectations On Strong Homes Unit
RAMBLER METALS & MINING : Provides Reminder of Upcoming Events
HAVELOCK EUROPA : Issues Profit Warning After Several Contracts Are Postponed
Most Read News
1d ago WHOLE FOODS MARKET : Jordan named president of Whole Foods’ Rockies division
1d ago GLENCORE : invests in Congo hydropower as solution to blackouts
1d ago SIMON PROPERTY : May Be Looking to Buy Macerich, Recent Transactions Indicate
1d ago MACERICH : 10 Must Reads for the CRE Industry Today (November 20, 2014)
1d agoDJOPEC Leaves Production Target Unchanged
Most recommended articles
5m ago BMW not interested in buying stake in Tesla - Wirtschaftswoche
5m agoDJWal-Mart, Target Report Strong Thanksgiving Day Traffic--3rd Update
6m ago Intesa says Coutts international arm less valuable than whole group
6m ago ECB says banks to return 5.86 billion euros in crisis loans
8m agoDJBank of Russia Moves to Stem Ruble Slide
Dynamic quotes  
ON
| OFF